Thomas E. Hughes

Thomas E. Hughes is the current Director at Viridian Therapeutics. Prior to this, they were the SVP, Scientific Affairs and Investor Relations Officer at Trevena, Inc. from February 2008 to November 2018. In this role, they were responsible for synthesizing and communicating scientific data and strategic objectives to internal and external stakeholders including financial markets, scientific community, media, and partners. Thomas also helped lead the New Drug Application and moderated FDA Advisory Committee meeting. Before Trevena, they were a Member of the Board of Directors at Quellis Biosciences, Inc. from November 2018 to January 2021 when it was acquired by Catabasis Pharmaceuticals, Inc (NASDAQ: CATB). Prior to their corporate roles, Thomas Hughes was an Adjunct Assistant Professor at Duke University Medical Center and a Research Assistant at the University of California, San Diego from September 1999 to July 2003.

Thomas E. Hughes has a B.S. in Chemical Pharmacology from Duke University, an M.B.A. in Health Sector Management from the Fuqua School of Business at Duke University, and a Ph.D. in Biomedical Sciences from the University of California, San Diego School of Medicine.